Share on StockTwits

MedAssets (NASDAQ:MDAS) posted its quarterly earnings results on Wednesday. The company reported $0.30 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.28 by $0.02, Stock Ratings reports. The company had revenue of $170.50 million for the quarter, compared to the consensus estimate of $165.64 million. During the same quarter in the prior year, the company posted $0.27 earnings per share. The company’s quarterly revenue was up 4.1% on a year-over-year basis. MedAssets updated its FY14 guidance to $1.33-1.43 EPS.

A number of analysts have recently weighed in on MDAS shares. Analysts at Citigroup Inc. initiated coverage on shares of MedAssets in a research note on Tuesday, February 18th. They set a “buy” rating on the stock. On the ratings front, analysts at RBC Capital initiated coverage on shares of MedAssets in a research note on Thursday, February 13th. They set a “sector perform” rating and a $21.00 price target on the stock. Finally, analysts at Zacks upgraded shares of MedAssets from an “underperform” rating to a “neutral” rating in a research note on Monday, January 6th. They now have a $20.50 price target on the stock. Eight investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.68.

Shares of MedAssets (NASDAQ:MDAS) traded up 1.05% on Wednesday, hitting $22.07. The stock had a trading volume of 642,006 shares. MedAssets has a 52 week low of $16.31 and a 52 week high of $26.58. The stock has a 50-day moving average of $21.23 and a 200-day moving average of $22.45. The company has a market cap of $1.365 billion and a price-to-earnings ratio of 260.00.

MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.